Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. (Nasdaq: AZTA) is a life sciences company focused on cold-chain sample management and multiomics services. News about AZTA often centers on how its sample management solutions, biorepository network and genomic services support drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions.
On this page, readers can follow company announcements related to financial results, segment performance in Sample Management Solutions and Multiomics, and updates on margin trends and cost structure. Earnings releases and accompanying commentary provide insight into revenue contributions from products and services, as well as the company’s efforts to streamline operations and refine its portfolio.
Azenta’s news flow also includes strategic transactions and capital allocation decisions, such as the definitive agreement to sell its B Medical Systems business and the authorization of a share repurchase program. These items illustrate how the company prioritizes core capabilities and balances investment in growth with returning capital to shareholders.
Another key theme in AZTA news is partnerships and collaborations. Recent releases describe Azenta’s role in supporting the PRECEDE Foundation’s pancreatic cancer early detection efforts through secure sample storage, and its collaboration with Frenova and Nephronomics, where GENEWIZ by Azenta provides genomic sequencing and Azenta manages long-term sample storage for a large kidney disease research program.
Investors and researchers can use this news feed to monitor developments in Azenta’s sample management and multiomics businesses, track major collaborations and stay aware of governance and shareholder-related events such as investor days, conference participation and annual meeting information.
Azenta (Nasdaq: AZTA) will host an Investor Day on Wednesday, December 10, 2025 at its biorepository facility in Indianapolis, Indiana. The event runs 8:30 AM–3:30 PM ET and includes an invite-only morning facility tour plus afternoon executive presentations and Q&A led by John Marotta (CEO) and Lawrence Lin (EVP & CFO).
The afternoon presentations will be webcast beginning at 1:00 PM ET, with a replay available the following day on Azenta's Investor Relations website. In-person attendance is by invitation and requires advanced registration.
Azenta (Nasdaq: AZTA) reported Q3 fiscal 2025 financial results with revenue from continuing operations at $144 million, flat year-over-year with a 2% organic decline. The company's performance showed mixed results across segments, with Multiomics revenue up 4% to $66 million, while Sample Management Solutions declined 4% to $78 million.
Notable improvements include Adjusted EBITDA of $18 million with a margin of 12.3%, up 260 basis points year-over-year, and Non-GAAP Diluted EPS of $0.19, up from $0.14 last year. The company maintains a strong financial position with $565 million in cash and equivalents. Azenta reiterated its fiscal 2025 guidance, expecting 3-5% organic revenue growth and approximately 300 basis points of Adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) has announced a strategic collaboration with Frenova and Nephronomics to advance genomic research in nephrology through the MyReason® genomics research program. The initiative has already registered over 35,000 participants and aims to reach 50,000 participants within two years.
Azenta will provide genomic sequencing through GENEWIZ and manage sample storage in its global biorepository network. Nephronomics, which holds exclusive commercial rights to the MyReason dataset, will utilize AI/machine learning models to analyze the comprehensive cardio-kidney-metabolic (CKM) disease data to identify novel disease subtypes, protective genetic variants, and therapeutic targets.
Fresenius Medical Care (NYSE:FMS) announced a strategic collaboration between its research organization Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences to advance genomic analysis of kidney disease through the My Reason® genomics program.
The collaboration leverages Frenova's registry of over 35,000 participants (targeting 50,000 in two years) to create the world's largest cardio-kidney-metabolic disease database. GENEWIZ will provide DNA sequencing and biospecimen storage, while Nephronomics holds exclusive commercial rights to develop targeted therapies using AI/ML models.
This initiative aims to transform kidney care through personalized medicine by analyzing genetic mechanisms underlying kidney, cardiovascular, and metabolic diseases.
Azenta (Nasdaq: AZTA) announced its participation in the upcoming 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The company's management team will attend the virtual event scheduled for Tuesday, August 12, 2025. This conference provides an opportunity for investors and analysts to engage with Azenta's leadership through one-on-one meetings.
Azenta (Nasdaq: AZTA) has scheduled its fiscal third quarter 2025 earnings announcement for Tuesday, August 5, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results for the quarter ended June 30, 2025.
Stakeholders can access the live webcast through the company's investor relations website. A replay of the event will become available starting at 8:30 a.m. ET on August 6, 2025.
Azenta's GENEWIZ division has formed a strategic partnership with Form Bio to enhance adeno-associated virus (AAV) gene therapy development. The collaboration integrates GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines to improve AAV gene therapy development workflows.
The partnership combines GENEWIZ's capabilities in synthesis, packaging of transgene expression cassettes, and long-read sequencing services with Form Bio's comprehensive AAV Genome Integrity Characterization using LAAVA software. This integration aims to streamline processes, reduce development time and costs, and provide better insights into AAV capsid contents for improved safety, efficacy, and manufacturability.
The partnership will be officially launched at the 27th Annual ASGCT Meeting in May 2025, where both companies will present their collaborative research.
Azenta (Nasdaq: AZTA) has scheduled its fiscal 2025 second quarter earnings announcement for Wednesday, May 7, 2025, before market opening. The earnings report will cover the quarter ended March 31, 2025.
The company will host a conference call and live webcast to discuss the financial results on May 7, 2025, at 8:30 a.m. Eastern Time. Investors, analysts, and media representatives can access the live webcast through Azenta's investor relations website. A replay of the event will be available starting May 8, 2025, at 8:30 a.m. ET.
Azenta (Nasdaq: AZTA) has released its 2024 Environmental, Social, & Governance (ESG) Report, outlining achievements across three main pillars: Environmental Protection, Social Impact, and Responsible Operations.
Key 2024 milestones include:
- ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions compared to 2022
- Over 60% electricity sourced from renewable sources
- Launch of BioArc™ Ultra for eco-friendly sample storage
- Introduction of LGBTQIA+ Employee Resource Group (Azenta PRISM)
- Implementation of Azenta THRIVE platform with LinkedIn Learning® integration
- 100% of global buyer team trained on sustainable sourcing
- EcoVadis® partnership expansion to evaluate ESG performance of over 50% of Tier 1 suppliers by spend